- Home
- SD vs KROS Comparison
SD vs KROS Comparison
Compare SD & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SD | KROS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 589.9M | 584.9M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SD | KROS |
|---|---|---|
| Price | $16.81 | $17.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 305.7K | ★ 311.1K |
| Earning Date | 03-09-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 40.92 | N/A |
| EPS | ★ 1.79 | 1.57 |
| Revenue | $155,930,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $31.95 | $6,924.79 |
| Revenue Next Year | $16.82 | N/A |
| P/E Ratio | ★ $9.01 | $10.95 |
| Revenue Growth | 29.68 | ★ 37798.31 |
| 52 Week Low | $8.81 | $9.12 |
| 52 Week High | $16.61 | $22.55 |
Technical Indicators
Market Signals| Indicator | SD | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 37.93 |
| Support Level | $15.69 | $17.22 |
| Resistance Level | $16.61 | $18.74 |
| Average True Range (ATR) | 0.51 | 0.66 |
| MACD | 0.09 | -0.12 |
| Stochastic Oscillator | 83.17 | 4.78 |
Price Performance
Historical ComparisonAbout SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.